• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Iris Acquisition Corp

    8/14/24 4:02:00 PM ET
    $IRAA
    Blank Checks
    Finance
    Get the next $IRAA alert in real time by email
    NT 10-Q 1 tm2421683-1_nt10q.htm NT 10-Q

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN
      ¨ Form N-CSR          

     

    For Period Ended: June 30, 2024

     

    ¨ Transition Report on Form 10-K

    ¨ Transition Report on Form 20-F

    ¨ Transition Report on Form 11-K

    ¨ Transition Report on Form 10-Q 

     

    For the Transition Period Ended:

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

     

     

     

     

    PART I
    REGISTRANT INFORMATION

     

    Iris Acquisition Corp

    Full Name of Registrant

     

    N/A

    Former Name if Applicable

     

    3rd Floor Zephyr House

    122 Mary Street, George Town

    PO Box 10085

    Address of Principal Executive Office (Street and Number)

     

    Grand Cayman KY1-1001, Cayman Islands

    City, State and Zip Code

     

     

     

     

    PART II
    RULE 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
    x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III
    NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Iris Acquisition Corp (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”) by the prescribed due date because the Company requires additional time to finalize its financial statements, other disclosures and reviews.

     

    The Company is working diligently to file the Form 10-Q as soon as possible; however, as a result of the circumstances described above, the Company is unable to file the Form 10-Q by the required due date of August 14, 2024 without unreasonable effort and expense.

     

    This report may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this report are forward-looking statements. When used in this report, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the Company or its management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the SEC. All subsequent written or oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 10-K. Copies of this filing, as well as the Company’s other filings, are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this report, except as required by law.

     

     

     

     

    PART IV
    OTHER INFORMATION

     

    (1)   Name and telephone number of person to contact in regard to this notification

     

    Sumit Mehta   971   1 4 3966949
    (Name)   (Area Code)   (Telephone Number)

    (2)   Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

     

    x Yes ¨ No

     

    (3)   Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ¨ Yes x No

     

    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    Iris Acquisition Corp
    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: August 14, 2024 /s/ Sumit Mehta
      By: Sumit Mehta
      Title: Chief Executive Officer

     

     

     

     

    Get the next $IRAA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Legion Partners Issues Letter to The Chefs' Warehouse, Inc. Shareholders Calling for Urgently Needed Board Change

    Highlights Company's Chronic Operational and Share Price Underperformance and the Need for New Skill Sets in the Boardroom to Help Chef Reach its Full Potential Nominates Four Highly Qualified, Independent Directors Who Would Bring Valuable Experience in Operations, Finance, Information Systems, Capital Allocation and Strategic Planning to the Board Legion Partners Asset Management, LLC, together with its affiliates (collectively, "we" or "Legion Partners"), is a significant shareholder of The Chefs' Warehouse, Inc. ("Chef", or the "Company") (NASDAQ:CHEF). Today, Legion Partners issued a public letter to the Company's shareholders announcing its nomination of four candidates to the Boa

    2/8/24 8:30:00 AM ET
    $AMPS
    $CHEF
    $F
    Electric Utilities: Central
    Utilities
    Food Distributors
    Consumer Discretionary

    Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

    NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (NASDAQ:IRAA), a publicly traded special purpose acquisition company ("SPAC") formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed "Liminatus Pharma, Inc.". The combined company's common stock is expected to be listed on the Nasdaq Capital Market. The transaction funding includes commitments for a $15

    12/5/22 7:00:00 AM ET
    $IRAA
    Blank Checks
    Finance

    Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments

    Businesses announce Definitive Business Combination Agreement and plan to operate under Liminatus Pharma The transaction values the combined companies at a pro forma enterprise value of $334 million The immune-modulating cancer treatments being developed by Liminatus are a GCC Vaccine, GCC CAR-T therapy and a CD47 immune checkpoint inhibitor. The GCC vaccine and CAR-T patent portfolio originated from Thomas Jefferson University (TJU). The CD47 checkpoint inhibitor originates from a South Korean biotech company InnoBation Bio Co. Ltd. The transaction is expected to be completed in the first half of 2023 Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company develo

    11/30/22 8:46:00 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    SEC Filings

    View All

    SEC Form 15-12G filed by Iris Acquisition Corp

    15-12G - Iris Acquisition Corp (0001831874) (Filer)

    4/30/25 9:25:13 AM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form 10-K filed by Iris Acquisition Corp

    10-K - Iris Acquisition Corp (0001831874) (Filer)

    4/15/25 9:48:28 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form NT 10-K filed by Iris Acquisition Corp

    NT 10-K - Iris Acquisition Corp (0001831874) (Filer)

    3/31/25 4:01:42 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Saba Capital Management, L.P. sold $8,781,435 worth of shares (853,395 units at $10.29) (SEC Form 4)

    4 - Iris Acquisition Corp (0001831874) (Issuer)

    9/28/23 10:05:40 AM ET
    $IRAA
    Blank Checks
    Finance

    New insider Moore Capital Management, Lp claimed ownership of 100,000 shares (SEC Form 3)

    3 - Iris Acquisition Corp (0001831874) (Issuer)

    9/26/23 4:43:11 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form 3: New insider Saba Capital Management, L.P. claimed ownership of 853,395 shares

    3 - Iris Acquisition Corp (0001831874) (Issuer)

    2/23/23 1:13:50 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    2/14/24 5:28:26 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    2/13/24 5:52:28 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    9/27/23 11:10:24 AM ET
    $IRAA
    Blank Checks
    Finance